Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, pragmatic use in patients with chronic intestinal disorders

Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, pragmatic use in patients with chronic intestinal disorders

Authors

  • Luigi Bonavina Surgery Unit, San Donato Hospital, Milan, Italy
  • Andrea Arini Gastroenterology Unit, Policlinico Paolo Giaccone, Palermo, Italy
  • Leonardo Ficano Gastroenterology Unit, Universioty of Palermo, Palermo, Italy
  • Donato Iannuzziello Digestive Endoscopy, Mater Dei Hospital, Bari, Italy
  • Luigi Pasquale Gastroenterology Unit, Avellino Hospital, Avellino, Italy
  • Salvo Emanuele Aragona Center of Regenerative Medicine, Humanitas Mater Domini, Castellanza (VA), Italy
  • Giorgio Ciprandi Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy
  • Italian Study Group on digestive disorders

Keywords:

inflammatory bowel disease, irritable bowel syndrome, diverticular disease, probiotic, survey

Abstract

Chronic intestinal disorders (CID), including inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn’s disease, irritable bowel syndrome (IBS), and diverticular disease (DD), are diseases that relapse episodes. There is evidence that patients with CID have intestinal dysbiosis, so probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 3,460 outpatients (1,660 males and 1,800 females, mean age 55 years) with chronic intestinal disorders. Patients took 1 stick/daily for 8 weeks. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients with chronic intestinal disorders.

Downloads

Published

10-07-2019

How to Cite

1.
Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, pragmatic use in patients with chronic intestinal disorders. Acta Biomed [Internet]. 2019 Jul. 10 [cited 2024 Jun. 13];90(7-S):8-12. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/8649

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>